ATR inhibition reverses the resistance of homologous recombination deficient MGMT(low)/MMR(proficient) cancer cells to temozolomide

The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMT(low/−ve)/MMR(proficient) patients benefit from TMZ treatment, indicating a need for additio...

Descripción completa

Detalles Bibliográficos
Autores principales: El Touny, Lara H., Hose, Curtis, Connelly, John, Harris, Erik, Monks, Anne, Dull, Angie B., Wilsker, Deborah F., Hollingshead, Melinda G., Gottholm-Ahalt, Michelle, Alcoser, Sergio Y., Mullendore, Michael E., Parchment, Ralph E., Doroshow, James H., Teicher, Beverly A., Rapisarda, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522839/
https://www.ncbi.nlm.nih.gov/pubmed/34676045
http://dx.doi.org/10.18632/oncotarget.28090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522839/
https://www.ncbi.nlm.nih.gov/pubmed/34676045
http://dx.doi.org/10.18632/oncotarget.28090

Ejemplares similares